ArticleVirchows Archiv : an international journal of pathology2006
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.
Article in Virchows Archiv : an international journal of pathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.International journal of molecular sciences · 2021Pooled it
- ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities.Cancers · 2025Review
- The versatile roles of ADAM8 in cancer cell migration, mechanics, and extracellular matrix remodeling.Frontiers in cell and developmental biology · 2023Review
- Expression levels of the metalloproteinase ADAM8 critically regulate proliferation, migration and malignant signalling events in hepatoma cells.Journal of cellular and molecular medicine · 2021Article
- Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases.Frontiers in molecular biosciences · 2021Review
- Article
- ADAM8 as a drug target in pancreatic cancer.Nature communications · 2015Article
- N-glycosylation regulates ADAM8 processing and activation.The Journal of biological chemistry · 2014Article
- Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer.BMC cancer · 2014Article
- Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression.Medical oncology (Northwood, London, England) · 2014Article
- Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis.Medical oncology (Northwood, London, England) · 2012Article
- Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma.Pathology oncology research : POR · 2012Article
- mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma.British journal of cancer · 2012Article
- Article
- The emerging role of matrix metalloproteases of the ADAM family in male germ cell apoptosis.Spermatogenesis · 2011Article
- Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Review
- ADAM8: a new therapeutic target for asthma.Expert opinion on therapeutic targets · 2009Review
- Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium: oncogenic and immunomodulations involving the action of tumor necrosis factor.Environmental health perspectives · 2008Article
- Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer.Cancer science · 2007Article
- ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer.Journal of cellular and molecular medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene products of the A disintegrin and metalloprotease (ADAM) family are critically involved in carcinogenesis and tumor progression of various solid tumors. Little is known about ADAM8 in prostate cancer. In our quest for novel diagnostic tissue markers of prostate cancer, we aimed to evaluate the expression of ADAM8 in prostate cancer and to correlate it with clinicopathological parameters. One hundred twenty-eight clinicopathologically characterized prostate cancer patients, with available follow-up data, were immunostained for ADAM8. Additionally, ADAM8 mRNA expression was quantified by real-time reverse transcription polymerase chain reaction (n = 59). ADAM8 protein expression was significantly associated with higher pT status, positive nodal status, and higher Gleason scores. Still, a significant prognostic value for the prostate-specific antigen relapse-free survival of ADAM8 could not be demonstrated. The differentiality of ADAM8 expression on protein and on mRNA level was low and partially inconclusive. Therefore, despite of its significant association with conventional parameters of an unfavorable prognosis, ADAM8 adds only limited information to the conventional histopathological assessment of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.